[en] The understanding of the method is a major concern when developing a stability-indicating method and even more so when dealing with impurity assays from complex matrices. In the presented case study, a Quality-by-Design approach was applied in order to optimize a routinely used method. An analytical issue occurring at the last stage of a long-term stability study involving unexpected impurities perturbing the monitoring of characterized impurities needed to be resolved. A compliant Quality-by-Design (QbD) methodology based on a Design of Experiments (DoE) approach was evaluated within the framework of a Liquid Chromatography (LC) method. This approach allows the investigation of Critical Process Parameters (CPPs), which have an impact on Critical Quality Attributes (CQAs) and, consequently, on LC selectivity. Using polynomial regression response modeling as well as Monte Carlo simulations for error propagation, Design Space (DS) was computed in order to determine robust working conditions for the developed stability-indicating method. This QbD compliant development was conducted in two phases allowing the use of the Design Space knowledge acquired during the first phase to define the experimental domain of the second phase, which constitutes a learning process. The selected working condition was then fully validated using accuracy profiles based on statistical tolerance intervals in order to evaluate the reliability of the results generated by this LC/ESI-MS stability-indicating method.
A comparison was made between the traditional Quality-by-Testing (QbT) approach and the QbD strategy, highlighting the benefit of this QbD strategy in the case of an unexpected impurities issue. On this basis, the advantages of a systematic use of the QbD methodology were discussed.
Research center :
Centre Interfacultaire de Recherche du Médicament - CIRM
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Hubert, Cédric ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Lebrun, Pierre ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Houari, Sabah ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Ziemons, Eric ; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie
Rozet, Eric ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Hubert, Philippe ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Language :
English
Title :
Improvement of a stability-indicating method by Quality-by-Design versus Quality-by-Testing: A case of a learning process
ICH, Q1A(R2), Stability testing of new drug substances and products (2003).
ICH, Q3B(R2), Impurities in new drug products (2006).
FDA, Code of Federal Regulations, Title 21, Section 211, Current good manufacturing practice for finished pharmaceuticals (Rockville, MD, 2012).
Görög S., Baertschi S.W. The role of analytical chemistry in drug-stability studies. Trends Anal. Chem. 2013, 10.1016/j.trac.2013.06.001.
U.S. Pharmacopeial Convention, new chapter 1224, 1225, 1226, USP panel expert.
ICH, Q8(R2), Pharmaceutical development (2009).
ICH, Q9, Quality risk management (2005).
ICH, Q10, Pharmaceutical quality system (2008).
Nethercote P., Ermer J. Quality by design for analytical methods: implications for method validation and transfer. Pharm. Technol. 2012, 36(10):52.
Orlandini S., Pinzauti S., Furlanetto S. Application of quality by design to the development of analytical separation methods. Anal. Bioanal. Chem. 2013, 405:443.
Debrus B., Lebrun P., Kindenge J.M., Lecomte F., Ceccato A., Caliaro C., Tayey Mbay J.M., Boulanger B., Marini R.D., Rozet E., Hubert P. Innovative high-performance liquid chromatography method development for the screening of 19 antimalarial drugs based on a generic approach, using design of experiments, independent component analysis and design space. J. Chromatogr. A 2011, 1218:5205.
Debrus B., Guillarme D., Rudaz S. Improved Quality-by-Design compliant methodology for method development in reversed-phase liquid chromatography. J. Pharm. Biomed. Anal. 2013, 84:215.
Schmidt A.H., Molnar I. Using an innovative Quality-by-Design approach for development of a stability indicating UHPLC method for ebastine in the API and pharmaceutical formulations. J. Pharm. Biomed. Anal. 2013, 78-79:65.
Cela R., Ordoñez E.Y., Quintana J.B., Rodil R. Chemometric-assisted method development in reversed-phase liquid chromatography. J. Chromatogr. A 2013, 1287:2.
Rozet E., Lebrun P., Hubert P., Debrus B., Boulanger B. Design Spaces for analytical methods. Trends Anal. Chem. 2013, 42:157.
Peterson J.J. A Bayesian approach to the ICH Q8 definition of design space. J. Biopharm. Stat. 2008, 18:959.
Lebrun P., Govaerts B., Debrus B., Ceccato A., Caliaro G., Hubert P., Boulanger B. Development of a new predictive modelling technique to find with confidence equivalence zone and design space of chromatographic analytical methods. Chemom. Intell. Lab. Syst. 2008, 91:4.
Debrus B., Lebrun P., Ceccato A., Caliaro G., Rozet E., Nistor I., Oprean R., Rupérez F.J., Barbas C., Boulanger B., Hubert P. Application of new methodologies based on design of experiments, independent component analysis and design space for robust optimization in liquid chromatography. Anal. Chim. Acta 2011, 691:33.
Lebrun P., Boulanger B., Debrus B., Lambert Ph., Hubert Ph. A Bayesian Design Space for analytical methods based on multivariate models and predictions. J. Biopharm. Stat. 2012, http://hdl.handle.net/2268/128222.
Peterson J.J. A posterior predictive approach to multiple response surface optimization. J. Qual. Technol. 2004, 36:139.
Peterson J.J., Snee R.D., McAllister P.R., Schofield T.L., Carella A.J. Statistics in pharmaceutical development and manufacturing. J. Qual. Technol. 2009, 41:111.
Peterson J.J., Yahyah M. A Bayesian Design Space approach to robustness and System Suitability for pharmaceutical assays and other processes. Stat. Biopharm. Res. 2009, 1:441.
Debrus B., Lebrun P., Rozet E., Schofield T., Kindenge J., Marini R., Rudaz S., Boulanger B., Hubert Ph. A new method for Quality-by-Design robust optimization in liquid chromatography. LC-GC Europe 2013, 26:370.
Maggio R.M., Vignaduzzo S.E., Kaufman T.S. Practical and regulatory considerations for stability-indicating methods for the assay of bulk drugs and drug formulations. Trends Anal. Chem. 2013, 10.1016/j.trac.2013.05.008.
Borman P., Nethercote P., Chatfield M., Thompson D., Truman K. The application of quality by design to analytical methods. Pharm. Technol. 2007, 31:142.
Gavin P.F., Olsen B.A. A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603). J. Pharm. Biomed. Anal. 2008, 46:431.
Rozet E., Wascotte V., Lecouturier N., Preat V., Dewé W., Boulanger B., Hubert Ph. Improvement of the decision efficiency of the accuracy profile by means of a desirability function for analytical methods validation. Application to a diacetyl-monoxime colorimetric assay used for the determination of urea in transdermal iontophoretic extracts. Anal. Chim. Acta 2007, 591:239.
Rozet E., Ceccato A., Hubert C., Ziemons E., Oprean R., Rudaz S., Boulanger B., Hubert Ph. Analysis of recent pharmaceutical regulatory documents on analytical method validation. J. Chromatogr. A 2007, 1158:111.